SCHEMBL5060424

SCHEMBL5060424

CNc1ncc2cc(-c3ccc(F)c(NC(=O)Nc4cc(C(C)(C)C)nn4-c4cccc(C#N)c4)c3)c(=O)n(C(C)C)c2n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 11/20 0.44
MAPK12 P53778 4/20 0.44
MAPK13 O15264 3/20 0.44
MAPK11 Q15759 3/20 0.44
MAP3K7 O43318 2/20 0.42
TAB1 Q15750 1/20 0.42
BRAF P15056 5/20 0.41
KRAS P01116 3/20 0.41
RAF1 P04049 3/20 0.41
KDR P35968 3/20 0.41
MAP2K2 P36507 2/20 0.41
MAP2K1 Q02750 2/20 0.41
CDK8 P49336 2/20 0.40
DYRK3 O43781 1/20 0.40
RPS6KB1 P23443 1/20 0.40
MARK3 P27448 1/20 0.40
FRK P42685 1/20 0.40
GSK3B P49841 1/20 0.40
MAP4K2 Q12851 1/20 0.40
STK3 Q13188 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5060216 0.93 MAPK14 (0.47) MAPK14MAPK12MAPK13MAPK11BRAF
SCHEMBL5052414 0.92 MAPK14 (0.51) MAPK14MAPK12MAPK13MAPK11BRAF
SCHEMBL5055067 0.92 BRAF (0.45) MAPK14MAPK12MAPK13MAPK11MAP3K7
SCHEMBL5052263 0.92 KCNJ6 (0.39) MAPK14MAPK12MAPK13MAPK11MAP3K7
SCHEMBL5062135 0.91 MAPK14 (0.52) MAPK14MAPK12MAPK13MAPK11BRAF
SCHEMBL5060085 0.91 BRAF (0.47) MAPK14MAPK12MAPK13MAPK11MAP3K7
SCHEMBL5052182 0.90 MAP3K7 (0.48) MAPK14MAPK12MAPK13MAPK11MAP3K7
SCHEMBL5054780 0.89 MAPK14 (0.44) MAPK14MAPK12MAPK13MAPK11BRAF
SCHEMBL5052979 0.89 MAPK14 (0.46) MAPK14MAPK12MAPK13MAPK11BRAF
SCHEMBL5062653 0.88 MAPK14 (0.50) MAPK14MAPK12MAPK13MAPK11BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080113967-A1 ENZYME MODULATORS AND TREATMENTS DECIPHERA PHARMACEUTICALS, LLC (US) 2008-05-15 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080113967-A1 ENZYME MODULATORS AND TREATMENTS ABL2, BRAF, MAP3K1 MAPK14 100/4885MAPK12 99/4885MAPK13 118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.